Management of Ureteral Colic with Naproxen and Buscopan
Primary Recommendation
Use naproxen (or another NSAID) as first-line therapy for acute ureteral colic; do not use buscopan (hyoscine-butylbromide) as it provides no clinically meaningful benefit for pain relief. 1, 2, 3
Naproxen for Ureteral Colic
Efficacy and Mechanism
NSAIDs like naproxen are highly effective for renal colic pain, achieving complete pain relief in 56% of patients within 30 minutes and 86% within one hour when administered parenterally. 4
NSAIDs work by inhibiting prostaglandin synthesis, which directly reduces renal pelvic pressure—the primary source of pain in ureteral obstruction. 5
NSAIDs reduce pain by approximately 3.84 cm on a 10 cm visual analogue scale at 30 minutes compared to placebo (though evidence certainty is low due to study heterogeneity). 2
NSAIDs significantly reduce the need for rescue analgesia compared to placebo (RR 0.24,95% CI 0.11-0.53), meaning patients are 76% less likely to require additional pain medication. 1
Dosing and Administration
Naproxen sodium 275 mg can be administered intramuscularly or intravenously for acute renal colic. 4
Intravenous administration may be superior to rectal routes (RR 0.35 for rescue medication need), though IV and IM routes appear equivalent. 2
NSAIDs demonstrate sustained analgesic effect with lower rates of pain recurrence compared to other medication classes. 6
Comparative Effectiveness
NSAIDs provide equivalent or superior pain relief compared to opioids at 30 minutes (MD -5.58,95% CI -10.22 to -0.95), with significantly fewer side effects including less vomiting (NNT 5) and less need for rescue analgesia (NNT 11). 6
NSAIDs are superior to paracetamol, requiring significantly less rescue analgesia (RR 0.56,95% CI 0.42-0.74). 6
Buscopan (Hyoscine-Butylbromide) for Ureteral Colic
Evidence Against Use
Buscopan provides NO reduction in opioid requirements when added to standard therapy (median morphine dose 0.12 mg/kg with buscopan vs 0.11 mg/kg with placebo, p=0.4). 7
Buscopan does NOT reduce the need for ongoing analgesia (33% required additional morphine with buscopan vs 38% with placebo, p=0.5). 7
Placebo is non-inferior to continuous IV buscopan infusion for pain relief in renal colic, with the upper confidence interval remaining below the non-inferiority threshold. 3
Buscopan has NO effect on upper urinary tract dynamics or renal pelvic pressure in acute obstruction, unlike NSAIDs which significantly reduce pressure. 5
Mechanism Failure
Anticholinergic/antispasmodic drugs do not address the pathophysiology of renal colic pain, which is primarily caused by increased renal pelvic pressure from prostaglandin-mediated inflammation and obstruction—not smooth muscle spasm. 5
The analgesic effect of buscopan as monotherapy is inferior to both opioids and NSAIDs, and any observed benefit is not sustained. 8
Clinical Bottom Line on Buscopan
There is no role for buscopan (continuous IV or otherwise) in the treatment of renal colic based on current evidence. 3
Buscopan does NOT facilitate stone passage and has no effect on stone expulsion rates. 8
Practical Treatment Algorithm
First-Line Therapy
Administer an NSAID immediately (naproxen 275 mg IM/IV, or alternative NSAIDs like ketorolac 30 mg IV, diclofenac 75 mg IM, or ibuprofen 800 mg IV). 1, 2, 6
Avoid buscopan entirely—it adds no benefit to NSAID therapy and wastes time and resources. 7, 3
Rescue Therapy
If NSAIDs provide inadequate relief within 30-60 minutes, add opioid analgesia (morphine 2.5-5 mg IV titrated to effect), but continue the NSAID for its sustained anti-inflammatory effect. 7, 6
Do NOT add buscopan to NSAIDs—combination therapy shows no superiority over NSAIDs alone (RR 1.00,95% CI 0.89-1.13). 1
Adjunctive Medical Expulsive Therapy
Consider tamsulosin 0.4 mg daily for distal ureteral stones >5 mm to facilitate stone passage (86% vs 79% expulsion rate compared to placebo, p<0.001) and provide additional pain relief. 9
Tamsulosin is NOT a substitute for acute analgesia but serves as adjunctive therapy to promote stone expulsion over days to weeks. 9
Important Caveats
Verify adequate renal function before NSAID administration—NSAIDs are contraindicated in severe renal impairment. 6
Major adverse effects from NSAIDs in renal colic are rarely reported in the literature, but monitor for gastrointestinal bleeding and renal function deterioration in high-risk patients. 1
The FDA-approved indication for buscopan is for equine colic, not human ureteral colic—its use in humans for this indication is off-label and unsupported by evidence. 10
Pain recurrence is less common with NSAIDs than with other analgesics, supporting their use as the primary agent rather than a secondary option. 1